Article
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2025
Riedl J M, Fece de la Cruz F, Lin J J, Parseghian C, Kim J E, Matsubara H, Barnes H, Caughey B, Norden B L, Morales-Giron A A, Kushner E W, Ehnstrom S, Nakamura H, Patel P S, Ellis H, Pappas L, Vakaris A, Gainor J F, Kopetz S, Klempner S J, Parikh A R, Hata A N, Heist R S, Corcoran R B
Abstract excerpt
BACKGROUND: Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the genomic landscape of acquired resistance to KRASG12Ci and to elucidate whether novel classes of KRAS inhibitors can overcome these resistance mechanisms. METHODS: To assess clinical frequencies of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.